Case 1: A 28-year-old Mestizo female with diffuse alveolar hemorrhage A 28-year-old Mestizo female was diagnosed with systemic lupus erythematosus (SLE) a year ago, based on fever, polyarthralgia/its, ...

Hemophagocytic lymphohistiocytosis (HLH) is a well-recognised complication of systemic lupus erythematosus (SLE). In one small case series, HLH was noted in approximately 5% of patients with lupus. 1 ...

Case 2: An Afro-Caribbean female with atypical chest pain An Afro-Caribbean female presented with neuropsychiatric lupus at the age of 28 years and was treated with intravenous cyclophosphamide. Her ...

Systemic lupus erythematosus (SLE) is associated with increased expression of genes regulated by Type I interferon (IFN) in 50–70% of patients. 1 Previous studies, including our own, have demonstrated ...

Immune dysregulation in systemic lupus erythematosus (SLE) results in the autoimmune manifestations of SLE, but also leads to an impaired immune response to pathogens and vulnerability to infections ...

A meta-analysis of the four relevant randomized clinical trials evaluating direct oral anticoagulants (DOACs) versus warfarin in thrombotic antiphospholipid syndrome (APS) showed a significant ...

Despite advancements in lupus management over the past two decades, infection remains a significant cause of morbidity and mortality among patients with systemic lupus erythematosus (SLE). 1 2 Various ...

As a consequence of increased survival over the last decades, patients with systemic lupus erythematosus (SLE) and their partners have an increased wish for pregnancy. However, pregnancy in SLE is ...

Introduction Treatment failures for lupus nephritis (LN) are high with 10%–30% of patients progressing to end-stage renal disease (ESRD) within 10 years. Interstitial fibrosis/tubular atrophy (IFTA) ...

Objectives Cardiovascular disease (CVD) is a leading cause of death in SLE. Coronary artery calcium (CAC) scores predict CVD events, independent of traditional risk factors. Patients with SLE aged >45 ...

Objectives To evaluate the time course of clinical response following anifrolumab treatment in patients with SLE. Methods A post hoc analysis was conducted using pooled data from phase III, randomised ...

Background A pharmacologic intervention that modulates JAK/STAT signaling pathways represents a novel approach for the treatment of Systemic Lupus Erythematosus (SLE). In animal models of SLE, ...